Singapore: GC-Rise Pharmaceutical exclusively sponsored a nation-wide anti-tumor academic exchange event initiated by the Committee of Gynecological Oncology, Chinese Anti-Cancer Association. The program will consist of several symposiums in more than 10 cities throughout the country, focusing on the diagnosis, treatment as well as the improvement of post-treatment life quality concerning gynecological tumors.

The committee held its first symposium in Beijing on May 27, in which GC-Rise jointly explored how to improve life quality for women patients who have received tumor-removal operations with the medical experts.

Professor Sheng Xiugui, a senior committee member of the association, said that, "Post-operation treatment is just as important as the operation itself; the life quality of patients after the operations should be given high attention."

Sheng cited Remifemin, introduced by GC-Rise, a herbal drug that treats some of the effects of menopause, as a preferred product to alleviate or eliminate the symptoms of menopause after operations or chemotherapy such as profuse sweating, insomnia or emotional instability. GC-Rise introduced Remifemin from Germany at the end of 2008.

After three years' expansion in China, its market share is now 11 percent, a top-three product in its segment. The company also teams up with CMC to make its voice heard through the CMC-GC-Rise Journal.